 |
 |

Aspirin Dose and Cardiovascular Disease Prevention
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
To the Editor: Dr Campbell and colleagues1 conducted a systematic review of aspirin dose in prevention of cardiovascular disease. I believe that their use of the differences in bleeding rate observed in the post hoc analysis of the aspirin only group of the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial2 warrants clarification.
On the assumption of 50 million patients taking aspirin in the United States, the authors state that "if the differences in major bleeding found in the aspirin-only group of the CURE trial are reflective of this population, daily treatment with 325 mg of aspirin would lead to an excess of more than 900 000 major bleeding events per year compared with a daily dose of 81 mg."1 This is a very big "if" and hence a disproportionately hypothetical figure.
The analysis of the results of the CURE trial by Peters et al2 was a retrospective subgroup . . . [Full Text of this Article]
Andrew Clegg, MBBS, BSc, MRCP
andrewpaulclegg@yahoo.co.uk Department of Geriatric Medicine Calderdale Royal Hospital Halifax, United Kingdom
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED LETTERS
Aspirin Dose and Cardiovascular Disease Prevention
George Kwok Chu Wong
JAMA. 2007;298(6):625.
EXTRACT
| FULL TEXT
Aspirin Dose and Cardiovascular Disease Prevention—Reply
Charles L. Campbell, Susan Smyth, Steven R. Steinhubl, and Gilles Montalescot
JAMA. 2007;298(6):625-626.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Charles L. Campbell, Susan Smyth, Gilles Montalescot, and Steven R. Steinhubl
JAMA. 2007;297(18):2018-2024.
ABSTRACT
| FULL TEXT
|